So far no markers or phenotypic functions have been shown to be unequivocally pathognomonic of glioma stem cells, although a number have been tried and reported, including immunophenotyping for markers other than CD133, side population analysis, aptamer selection, and intrinsic autofluorescence [9–14]. This evidence concerns the gene PROM1 and central nervous system cancer.